CJC-1295 vs Ipamorelin (2026): Evidence & Regulatory Status Compared

CJC-1295 and Ipamorelin are both unapproved research peptides used to raise growth hormone, and they act on different receptors — CJC-1295 is a long-acting GHRH analog, Ipamorelin is a selective ghrelin-receptor agonist — which is why they are often stacked. Neither has a published human RCT supporting the anti-aging or performance uses they are marketed for. Both were removed from the FDA's 503A Category 2 list in April 2026 and remain under Pharmacy Compounding Advisory Committee review, not eligible for compounding. Both are prohibited in sport. Research information only, not medical advice.

Last updated:

Independent information index. We do not sell vendor placements or take affiliate commissions on peptide sales. Read our affiliate disclosure .

CJC-1295 Ipamorelin
Peptide class Long-acting GHRH analog (acts on the GHRH receptor) Selective ghrelin-receptor agonist (growth-hormone secretagogue)
Evidence level (highest) Early-phase human pharmacology, otherwise preclinical Some discontinued clinical trials, otherwise preclinical
Published human RCT (for marketed uses) None as of June 2026 None as of June 2026
Most-studied effect Raising growth-hormone and IGF-1 levels Pulsatile growth-hormone release without raising cortisol/prolactin
US drug approval status Unapproved drug Unapproved drug
FDA 503A compounding Removed from Category 2 (Apr 2026); under PCAC review, not compoundable Removed from Category 2 (Apr 2026); under PCAC review, not compoundable
WADA status Prohibited (S2, growth-hormone releasing factors) Prohibited (S2, growth-hormone secretagogue)
EU marketing authorization None None

Verdict

CJC-1295 and Ipamorelin are stacked together precisely because they are not the same thing: CJC-1295 is a long-acting GHRH analog that pushes on the GHRH receptor, while Ipamorelin is a selective ghrelin-receptor agonist that triggers a growth-hormone pulse without the cortisol and prolactin rise seen with older secretagogues. On the two things that actually matter, though, they converge: neither has a published human randomized controlled trial supporting the anti-aging or body-composition uses they are sold for, and both are unapproved drugs that were pulled from the FDA's 503A Category 2 list in April 2026 and remain under PCAC review — not compoundable, not approved. Both are also prohibited in sport. The stack is a mechanism story, not an evidence story.

CJC-1295 and Ipamorelin show up in the same sentence so often that many people assume they are interchangeable. They are not — and the reason they are usually combined rather than chosen between is the most useful thing to understand about them. The table above is the row-by-row breakdown. Below is what each row means.

CJC-1295 vs Ipamorelin: the short version

Both are unapproved research peptides used to raise growth hormone, but they work through different receptors: CJC-1295 is a long-acting GHRH analog, Ipamorelin a selective ghrelin-receptor agonist. Neither has a published human randomized controlled trial for the anti-aging or body-composition uses they are marketed for, and both sit in the same 2026 regulatory limbo.

Mechanism: why they get stacked

This is the real difference. CJC-1295 mimics growth-hormone-releasing hormone (GHRH) and, in its DAC form, stays active far longer than natural GHRH, raising the baseline on which growth-hormone pulses ride. Ipamorelin works on a different receptor entirely — it is a selective agonist at the ghrelin/growth-hormone-secretagogue receptor, triggering a growth-hormone pulse without the cortisol and prolactin spikes of older secretagogues. Because the two push the same output through two different doors, they are typically combined rather than compared. The synergy is a plausible mechanism, not a proven clinical outcome.

Evidence: thin on both sides

For how we weigh evidence tiers, see our how we grade evidence explainer, the full CJC-1295 evidence and regulatory record, and the Ipamorelin evidence and regulatory record. In short: CJC-1295 has early-phase human pharmacology data showing it raises growth-hormone and IGF-1 levels, but no controlled trials of the outcomes people buy it for; Ipamorelin was taken into clinical trials (for postoperative ileus) that were discontinued, and its remaining record is largely preclinical. Neither has a published RCT supporting anti-aging, fat loss or performance.

Regulation: the same 2026 limbo

Both peptides were removed from the FDA 503A “do not compound” Category 2 list in April 2026 after their nominations were withdrawn, per Frier Levitt’s analysis. Removal did not make either compoundable; both remain under Pharmacy Compounding Advisory Committee review and neither is an FDA-approved drug. In sport, both are prohibited at all times under the WADA S2 category for growth-hormone-releasing factors and secretagogues. Neither carries an EU marketing authorization.

So which one, if either?

The honest framing is that this is not really an either/or. They are two unproven research peptides with complementary mechanisms and the same regulatory and anti-doping status. If the question is “which is the proven choice,” the answer is neither — there is no controlled human evidence for the uses they are marketed for.

Research information only. Neither CJC-1295 nor Ipamorelin is approved for human use. Talk to a licensed physician before considering any peptide.

FAQ

Is CJC-1295 or Ipamorelin FDA approved?
Neither. Both are unapproved drugs in the United States. Both were removed from the FDA "do not compound" Category 2 list in April 2026 after their nominations were withdrawn, but removal did not make them eligible for compounding — they remain under Pharmacy Compounding Advisory Committee review.
Why are CJC-1295 and Ipamorelin used together?
They act on different receptors. CJC-1295 is a GHRH analog and Ipamorelin is a selective ghrelin-receptor agonist, so combining them is intended to produce a larger, more natural growth-hormone pulse. This is a mechanistic rationale; there is no published human RCT showing the combination is safe and effective for anti-aging or performance.
Are they banned in sport?
Yes. Growth-hormone-releasing factors and secretagogues — including CJC-1295 and Ipamorelin — are prohibited at all times under WADA category S2. This page is research information, not medical or legal advice.

Sources